Vir Biotechnology, Inc. - Common Stock (VIR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
VIR on Nasdaq
Shares outstanding
137,278,139
Price per share
$6.03
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
107,007,238
Total reported value
$610,804,629
% of total 13F portfolios
0%
Share change
-3,814,557
Value change
-$20,189,079
Number of holders
209
Price from insider filings
$6.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vir Biotechnology, Inc. - Common Stock (VIR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% $81,987,996 14,826,039 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 209 institutional investors reported holding 107,007,238 shares of Vir Biotechnology, Inc. - Common Stock (VIR). This represents 78% of the company’s total 137,278,139 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Vir Biotechnology, Inc. - Common Stock (VIR) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SB INVESTMENT ADVISERS (UK) LTD 12% 16,684,041 0% 0.72% $95,265,874
BlackRock, Inc. 12% 15,967,656 -1.1% 0% $91,175,315
ARCH Venture Management, LLC 9.4% 12,916,663 0% 15% $73,754,146
VANGUARD GROUP INC 9.3% 12,799,381 -3.2% 0% $73,084,465
STATE STREET CORP 3.8% 5,241,293 -0.26% 0% $29,927,783
FMR LLC 2.6% 3,637,130 +2.2% 0% $20,768,011
DIMENSIONAL FUND ADVISORS LP 2.2% 2,978,871 -0.97% 0% $17,008,661
MORGAN STANLEY 2% 2,689,118 +65% 0% $15,354,867
ORBIMED ADVISORS LLC 1.7% 2,380,715 0% 0.33% $13,593,883
GEODE CAPITAL MANAGEMENT, LLC 1.6% 2,246,222 -0.28% 0% $12,828,245
Aberdeen Group plc 1.1% 1,526,265 +52% 0.01% $8,714,973
GOLDMAN SACHS GROUP INC 1.1% 1,521,802 +18% 0% $8,689,490
MILLENNIUM MANAGEMENT LLC 1% 1,396,504 +129% 0.01% $7,974,038
RENAISSANCE TECHNOLOGIES LLC 0.85% 1,167,100 +9.6% 0.01% $6,664,141
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 1,142,879 -12% 0% $6,525,839
Hudson Bay Capital Management LP 0.66% 911,882 +31% 0.03% $5,206,846
NORTHERN TRUST CORP 0.66% 907,126 -2.3% 0% $5,179,689
CITADEL ADVISORS LLC 0.58% 799,034 -77% 0% $4,562,484
ROYAL BANK OF CANADA 0.52% 716,388 +1.3% 0% $4,090,000
NORDEA INVESTMENT MANAGEMENT AB 0.52% 714,561 +1.4% 0% $3,930,086
TWO SIGMA INVESTMENTS, LP 0.47% 649,300 +76% 0.01% $3,707,503
Clarius Group, LLC 0.45% 619,312 +0.29% 0.21% $3,536,272
Ikarian Capital, LLC 0.43% 593,374 -44% 0.77% $3,388,167
Bank of New York Mellon Corp 0.41% 557,018 -9.1% 0% $3,180,574
Ensign Peak Advisors, Inc 0.4% 554,981 -4.8% 0.01% $3,168,942

Institutional Holders of Vir Biotechnology, Inc. - Common Stock (VIR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 724,002 $4,233,732 -$631,927 $6.03 9
2025 Q3 107,007,238 $610,804,629 -$20,189,079 $5.71 209
2025 Q2 110,838,661 $558,775,027 +$84,580,493 $5.04 211
2025 Q1 93,307,654 $604,781,149 +$27,869,786 $6.48 230
2024 Q4 88,707,815 $651,128,647 +$14,508,869 $7.34 202
2024 Q3 87,600,991 $656,229,927 -$4,690,938 $7.49 196
2024 Q2 88,070,124 $783,797,629 -$8,197,439 $8.90 214
2024 Q1 88,672,968 $898,219,887 +$5,728,031 $10.13 204
2023 Q4 62,772 $638,110 -$466,538 $10.18 2
2023 Q3 87,135,246 $816,460,660 -$230,849,877 $9.37 207
2023 Q2 89,954,960 $2,206,557,684 +$34,905,586 $24.53 218
2023 Q1 88,346,582 $2,055,832,957 +$54,068,665 $23.27 223
2022 Q4 86,037,339 $2,177,601,443 -$13,342,584 $25.31 215
2022 Q3 85,588,569 $1,650,323,775 -$5,282,843 $19.28 200
2022 Q2 85,797,926 $2,177,148,256 +$132,562,865 $25.47 196
2022 Q1 80,955,346 $2,081,872,511 +$26,610,297 $25.72 184
2021 Q4 77,970,192 $3,247,066,292 +$168,069,474 $41.87 197
2021 Q3 74,436,666 $3,239,374,392 -$19,337,399 $43.52 168
2021 Q2 74,123,438 $3,504,460,413 +$64,555,007 $47.28 156
2021 Q1 74,771,091 $3,833,166,594 -$96,785,305 $51.27 146
2020 Q4 76,043,014 $2,036,590,926 +$148,788,769 $26.78 128
2020 Q3 69,392,501 $2,383,198,955 +$548,651,255 $34.33 113
2020 Q2 53,528,343 $2,192,848,258 +$657,404,867 $40.97 107
2020 Q1 37,861,777 $1,297,519,769 -$4,030,120 $34.27 60
2019 Q4 36,584,366 $460,028,000 +$460,027,647 $12.57 38